Economic EvaluationCost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective
Under an Elsevier user license
open archive
Keywords
secukinumab
psoriatic arthritis
cost-effectiveness
Argentina
interleukin-17A inhibitor
tumor necrosis factor inhibitors
incremental cost-effectiveness ratio
quality-adjusted life year
Cited by (0)
Conflict of interest: The authors have indicated that they have no conflicts of interest with regard to the content of this article.
© 2019 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.